Keros Therapeutics Inc (KROS)

Finanzdaten der Keros Therapeutics Inc-Aktie (KROS)

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Revenues	100.00%-	0.03	0.38	14.12	18.17
	17.88%30.94	26.24	29.66	29.65	57.99
Research and Development	38.73%22.33	16.10	17.91	19.52	43.50
Operating Income/Loss	19.55%-30.94	-25.88	-29.27	-15.38	-39.82
Nonoperating Income/Loss	2.67%2.23	2.17	4.30	6.68	6.90
Income/Loss From Continuing Operations Before Tax	21.10%-28.71	-23.71	-24.98	-8.70	-32.92
Income Tax Expense/Benefit	-	-	-1.51	-1.42	-2.22
	21.10%-28.71	-23.71	-23.46	-7.28	-30.70
Attributable To Parent	21.10%-28.71	-23.71	-23.46	-7.28	-30.70
Available To Common Stockholders, Basic	21.10%-28.71	-23.71	-23.46	-7.28	-30.70
Basic Average Shares	0.87%19.80	19.63	-3.38	40.62	40.61
Diluted Average Shares	0.87%19.80	19.63	-3.34	40.62	40.61
Basic Earnings Per Share	19.83%-1.45	-1.21	-0.38	-0.18	-0.76
Diluted Earnings Per Share	19.83%-1.45	-1.21	-0.38	-0.18	-0.76